Amikacin liposomal (Insmed)

阿米卡星脂质体 (Insmed)

Report date: 2025/01/16 20:00:08

Base Information

Drug NameAmikacin liposomal (Insmed)
Drug Alias NameALIS阿米卡星脂质体吸入悬浮液SLITLiposomal amikacin inhalation, LAILAI +[16] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action30S ribosomal subunit inhibitors
Targets30S ribosomal subunit
Therapy Area/IndicationsCystic FibrosisRespiratory Tract InfectionsMycobacterium Infections, Nontuberculous
Global Approved IndicationsRespiratory Tract Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2020/10/27
Country/TerritoryBelgiumUkraineSlovakia +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTransave Inc
China Registration ClassN/A

Develop Information

Active CompaniesInsmed Netherlands BvTaiba Middle East FZ LLC
Inactive CompaniesInsmed Inc
Active IndicationsRespiratory Tract Infections
Inactive IndicationsCystic FibrosisMycobacterium Infections, Nontuberculous

Other Information

ATC CodeN/A
Related LinksN/A